10q is out. Note that outstanding shares increased less

New Post Public Reply Private Reply Replies (1) Message Board
Mo
665
10q is out. Note that outstanding shares increased less than 10M shares in Q3 demonstrating Leo’s continual efforts to keep dilution at a minimal as IPIX advance their science. Detailed Outstanding share count went from 202,631,923 to 212,369,124 between 6/30/19 and 9/30/19 or 9,737,201 shares total.
IPIX received $400k in upfront cash on the Alfasigma IBD partnership which is in the range I was expecting. When IPIX announced the Alfasigma deal and did not follow up immediately with a B-OM phase 3 announcement that was a "tell" that they did not have enough resources to pay for a B-OM phase 3. The Alfasigma deal IMO is strategic in that some development and science advancement costs have been offloaded to Alfasigma and the deal further validates the Brilacidin science in addition to FDA validation. The B-IBD foam/enema market is a relatively small share of the overall IBD market and the partnership deal terms and conditions parallel this. My above sticky was written at a point that I was expecting the Term Sheet to produce a larger partnership but I now believe the 2nd partnership will be the significant one. A Brilacidin pill that will target specific areas to address the Colitis and Crohn's disease markets represent the largest Brilacidin revenue opportunities IMO. I believe the next partnership will be valued based on this enormous market opportunity and have significant upfront dollars which will limit further IPIX SP dilution. The bashers have been trying to set false narratives over what dictates a success/failure based of the dollar amount of upfront payments. I also found it interesting in the 10q that 60% of the OM market opportunity is represented in 500 locations and that a "small sales force" could cover this OM market opportunity. Some investors have indicated in the past that IPIX could take B-OM to market on their own and whether they do or not, the option is certainly possible if the right partnership deal for B-OM does not come along. An example is that an IBD pill partnership deal of significance gets inked in early to mid 2020 but that no B-OM deal had been struck yet. IPIX could decide to take up front monies from a large IBD pill partnership and allocate funds to do the B-OM phase 3 on their own and hire a small sales/manufacture-rep arrangement to sell B-OM where IPIX keeps 90% of revenue vs 12-15% on a license deal. I think having multiple options is always a good thing especially in a negotiation environment. I do not personally believe that any Longs are selling at these ridiculously compressed prices and the ONLY thing the criminals control is the SHORT TERM share price. As the criminals do their best to set new 52 week lows, there are many of us Longs that have been able to add to our positions and lower our average share price. With more shares in strong hands the eventual rise in SP could be significant. I am personally confident in the long term success of IPIX but this has been a major test in patience for all involved.

1

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 174

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 127

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 65

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 69

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 252

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 25

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 7

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 11

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Plumas Bancorp Increases Shareholder Value with Dividend

Updated Category News Views 100

Plumas Bancorp Announces Quarterly Cash Dividend Plumas Bancorp (Nasdaq: PLBC), the parent company of Plumas Bank, has recently made an important announcement regarding its financial strategy. The Board of Directors has declared a regular quarterly cash dividend of $0.30 per share on common stock, as a testament to the company's ongoing commitment to delivering value to...

Continue Reading
DTE Energy's Junior Subordinated Debentures Offer: Key Insights

Updated Category News Views 168

DTE Energy's Junior Subordinated Debentures Introduction DTE Energy Company (NYSE: DTE) has made a significant announcement regarding its financial strategies through the pricing of its 2025 Series H 6.25% Junior Subordinated Debentures. This offering, valued at $600 million in aggregate principal, is designed for various financial maneuvers that could solidify DTE's...

Continue Reading
Key Insights on SCOR's Share Capital and Voting Rights Details

Updated Category News Views 294

Understanding SCOR's Recent Share Capital Declaration On a notable date, SCOR made a significant announcement regarding its share capital. The communication was essential for understanding the current status of total shares and voting rights. As a leading global reinsurer, SCOR's declarations provide crucial insights into its financial health and operational metrics....

Continue Reading
Enthusiast Gaming's Record-Breaking Spectacle at Luminosity Event

Updated Category News Views 100

Enthusiast Gaming's Luminosity Invitational Shines Bright Enthusiast Gaming Holdings Inc. ('Enthusiast Gaming' or the 'Company'), a dynamic leader in the gaming and media sector, has made waves recently with its spectacular Luminosity Invitational: Back 2 School. This thrilling Super Smash Bros Ultimate event drew in a staggering estimate of over 400,000 unique online...

Continue Reading
UAB Kvartalas Closes Subscription Early for Latest Bonds

Updated Category News Views 128

UAB Kvartalas Closes Subscription for 4th Tranche of Bonds UAB "Kvartalas", a legal entity committed to facilitating growth and innovation, has made a significant announcement regarding its bond issuance process. The company, registered with the legal code 305475438, has its headquarters situated at Jogailos St. 4, Vilnius, Republic of Lithuania. In response to...

Continue Reading